WO2010004571A2 - Process for purification of rabeprazole sodium - Google Patents
Process for purification of rabeprazole sodium Download PDFInfo
- Publication number
- WO2010004571A2 WO2010004571A2 PCT/IN2008/000433 IN2008000433W WO2010004571A2 WO 2010004571 A2 WO2010004571 A2 WO 2010004571A2 IN 2008000433 W IN2008000433 W IN 2008000433W WO 2010004571 A2 WO2010004571 A2 WO 2010004571A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rabeprazole
- sodium
- stirred
- added
- rabeprazole sodium
- Prior art date
Links
- ZGDLVKWIZHHWIR-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2CCOCC2)N=C1 ZGDLVKWIZHHWIR-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229960001778 rabeprazole sodium Drugs 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims description 14
- 238000000746 purification Methods 0.000 title description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 12
- 229960004157 rabeprazole Drugs 0.000 abstract description 10
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 229940073584 methylene chloride Drugs 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229960002668 sodium chloride Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- -1 sulfoxide compound Chemical class 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- BSXAHDOWMOSVAP-UHFFFAOYSA-N 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfanyl]-1h-benzimidazole Chemical compound COCCCOC1=CC=NC(CSC=2NC3=CC=CC=C3N=2)=C1C BSXAHDOWMOSVAP-UHFFFAOYSA-N 0.000 description 1
- KNYNPBSPFHFPML-UHFFFAOYSA-N 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfonyl]-1h-benzimidazole Chemical compound COCCCOC1=CC=NC(CS(=O)(=O)C=2NC3=CC=CC=C3N=2)=C1C KNYNPBSPFHFPML-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a process for obtaining pure rabeprazole sodium.
- Xhe present invention also relates to a novel process for the preparation rabeprazole sodium amorphous form, and to a pharmaceutical composition comprising it.
- Rabeprazole sodium is an inhibitor of the gastric proton pump. It suppress gastric acid secretion by inhibiting the gastric H + , K + ATPase at the secretory surface of the gastric parital cell and blocks the final step of gastric acid secretion.
- Rabeprazole sodium is a sulfoxide compound have been prepared by oxidizing thioether compound with an oxidizing agent such as hydrogen peroxide, m-chloroperbenzoic acid, sodium hypochlorite, sodium hypobromite etc., as described in JP-A1-6270 (EP 268956), US 5045552). Rabeprazole represented by following structure:
- Japanese patent application JP2001039975 indicates that the product obtained by example 33 of U.S. patent No. 5045552 with a melting point of 140- 141 0 C corresponds to amorphous rabeprazole sodium.
- the X- ray powder diffraction pattern of the amorphous rabeprazole sodium is shown.
- U.S. patent No. 6180652 concerns process for the purification of rabeprazole and its pharmaceutically acceptable salts for its sulfone impurity, via: acetone complex of the rabeprazole or its pharmaceutically acceptable salts.
- rabeprazole sodium in amorphous form is obtained by lyophilizing an aqueous solution of rabeprazole sodium acetone complex.
- lyophilization is a technique which is not suitable for production at industrial scale because this process presents serious limitations on cost, time, equipment capability and environmental protection.
- WO 2004/085424 A1 refers to the conversion of the rabeprazole sodium acetone complex into amorphous rabeprazole sodium by heating at elevated temperatures, preferably between 100 and 110 0 C. It is well known that exposing rabeprazole-type compounds to high temperatures increases the risk of decomposition to form impurities and as such, heat treatment of rabeprazole sodium acetone complex into amorphous rabeprazole sodium is not adequate for the production of a rabeprazole which is suitable for pharmaceutical use.
- a process for preparing amorphous rabeprazole sodium comprises: a) Mixing a solution of rabeprazole sodium in a chlorinated solvent with cyclohexane, b) stirring the contents obtained in step (a) at 0-50 0 C for at least 15 minutes, and c) isolating amorphous rabeprazole sodium from the contents obtained in step (b).
- the solution of rabeprazole sodium in the chlorinated solvent may be obtained for example, by dissolving rabeprazole sodium in the chlorinated solvent or as a part of reaction mass obtained by reaction of rabeprazole with a base such as sodium hydroxide.
- the chlorinated solvent used in step (a) may preferably be methylene chloride, ethylene chloride or chloroform; or a mixture thereof.
- the more preferred chlorinated solvent is methylene chloride.
- the stirring in step (b) may preferably carried out at 20-35 0 C for 15 to 75 minutes, more preferably at 15 to
- Preparation of the amorphous rabeprazole sodium may occur during step (b).
- the precipitated solid may be isolated from the contents by methods such as filtration or ce ⁇ trifugation. If required the isolation of the amorphous rabeprazole sodium may be performed by the methods known in the art such as by cooling, using an antisolvent, by partial evaporation or a combination thereof followed by filtration or a centrifugation.
- the bottom organic layer was separated twice by treating with methylene chloride (2 x 250 L), stirred and allowed to settle for 15 minutes.
- Water (1300 L) and sodium hydroxide flakes (50 Kg) were added to the reactor, cooled to 20 - 25 0 C and then added the methylene chloride layer to the reactor.
- Sodium chloride (50 Kg) was added to the reaction mixture, stirred for 20 minutes and allowed to settle for 20 minutes.
- the bottom organic layer was separated.
- the pH of the aqueous layer was adjusted to 9.2 - 9.4 with ammonium acetate solution (ammonium acetate: 52 Kg + water: 200 L) and acetic acid solution (acetic acid: 65 L + water: 200 L).
- the bottom organic layer was separated twice by treating with methylene chloride (2 x 650 L), stirred and allowed to settle for 15 minutes.
- the organic layer was given carbon treatment, filtered and washed the filtrate with methylene chloride (50 L). Dried the total organic layers with sodium sulfate (20 Kg) and 2-Amino ethanol (1.8 L) was added. The organic layer was concentrated until the mass temperature reached to 40 - 45 0 C.
- Acetonitrile (50 L) was added to the reaction mass and acetonitrile was distilled off from the reaction mass until the mass temperature reached to 40 - 45 0 C.
- Acetonitrile (600 L) was added to the reaction mass, stirred for 2 hours at room temperature and cooled to 0 - 5 0 C.
- the total organic layer was washed with sodiumchloride solution (sodium chloride: 36 Kg, DM water: 140 L), given carbon treatment, filtered, washed the filtrate with methylenechloride (50 L) and 2-amino ethanol (0.54 L) was added.
- the organic layer was concentrated until the mass temperature reached to 35 - 40 0 C.
- Acetonitrile (90 L) was added to the reaction mass and acetonitrile was distilled off from the reaction mass until the mass temperature reached to 35 - 40 0 C.
- Acetonitrile (270 L) was added to the reaction mass, cooled to 25 - 35 0 C, stirred for 1 hour 30 minutes, cooled to 0 - 5 0 C and stirred for 1 hour.
- Rabeprazole was added to the solution and stirred at 25 - 35 0 C for 1 hour. Methanol was distilled off from the reaction mass, dichloromethane (150 L) was added to the residual mass and the contents were stirred to obtain solution. The solution was added to cyclohexane (1080 L). The contents were stirred at 25 - 35 0 C for 30 minutes, centrifuged the material and washed at 60 - 65 0 C to obtain 69 Kg of amorphous rabeprazole sodium.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There is provided a process for preparing amorphous rabeprazole sodium. Thus, for example, sodium hydroxide was dissolved in methanol. Rabeprazole was added to the solution and stirred at 25 - 35°C for 1 hour. Methanol was distilled off from the reaction mass, dichloromethane was added to the residual mass and the contents were stirred to obtain solution. The solution was added to cyclohexane. The contents were stirred at 25 - 35°C for 30 minutes, centrifuged the material and washed at 60 - 65°C to obtain amorphous rabeprazole sodium.
Description
PROCESS FOR PURIFICATION OF RABEPRAZOLE SODIUM
FIELD OF THE INVENTION
The present invention relates to a process for obtaining pure rabeprazole sodium. Xhe present invention also relates to a novel process for the preparation rabeprazole sodium amorphous form, and to a pharmaceutical composition comprising it.
BACKGROUND OF THE INVENTION
Rabeprazole sodium is an inhibitor of the gastric proton pump. It suppress gastric acid secretion by inhibiting the gastric H+, K+ ATPase at the secretory surface of the gastric parital cell and blocks the final step of gastric acid secretion. Rabeprazole sodium is a sulfoxide compound have been prepared by oxidizing thioether compound with an oxidizing agent such as hydrogen peroxide, m-chloroperbenzoic acid, sodium hypochlorite, sodium hypobromite etc., as described in JP-A1-6270 (EP 268956), US 5045552). Rabeprazole represented by following structure:
Japanese patent application JP2001039975 indicates that the product obtained by example 33 of U.S. patent No. 5045552 with a melting point of 140- 1410C corresponds to amorphous rabeprazole sodium. In this application, the X- ray powder diffraction pattern of the amorphous rabeprazole sodium is shown.
The process referred in example 33 of U.S. Patent No. 5045552 is that during the oxidation of the rabeprazole thioether compound, the obtained sulfoxide compound suffers a further oxidation generating the undesired sulfone (2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfonyl]-1H- benzimidazole) impurity.
U.S. patent No. 6180652 concerns process for the purification of rabeprazole and its pharmaceutically acceptable salts for its sulfone impurity, via: acetone complex of the rabeprazole or its pharmaceutically acceptable salts.
In the reference example 1 of U.S. patent 6180652 rabeprazole sodium in amorphous form is obtained by lyophilizing an aqueous solution of rabeprazole sodium acetone complex.
However, lyophilization is a technique which is not suitable for production at industrial scale because this process presents serious limitations on cost, time, equipment capability and environmental protection.
WO 2004/085424 A1 refers to the conversion of the rabeprazole sodium acetone complex into amorphous rabeprazole sodium by heating at elevated temperatures, preferably between 100 and 1100C. It is well known that exposing rabeprazole-type compounds to high temperatures increases the risk of decomposition to form impurities and as such, heat treatment of rabeprazole sodium acetone complex into amorphous rabeprazole sodium is not adequate for the production of a rabeprazole which is suitable for pharmaceutical use.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention there is provided a process for preparing amorphous rabeprazole sodium the said process comprises: a) Mixing a solution of rabeprazole sodium in a chlorinated solvent with cyclohexane, b) stirring the contents obtained in step (a) at 0-500C for at least 15 minutes, and c) isolating amorphous rabeprazole sodium from the contents obtained in step (b).
The solution of rabeprazole sodium in the chlorinated solvent may be obtained for example, by dissolving rabeprazole sodium in the chlorinated solvent or as a part of reaction mass obtained by reaction of rabeprazole with a base such as sodium hydroxide.
The chlorinated solvent used in step (a) may preferably be methylene chloride, ethylene chloride or chloroform; or a mixture thereof. The more preferred chlorinated solvent is methylene chloride. The stirring in step (b) may preferably carried out at 20-350C for 15 to 75 minutes, more preferably at 15 to
60 minutes.
Preparation of the amorphous rabeprazole sodium may occur during step (b). The precipitated solid may be isolated from the contents by methods such as
filtration or ceπtrifugation. If required the isolation of the amorphous rabeprazole sodium may be performed by the methods known in the art such as by cooling, using an antisolvent, by partial evaporation or a combination thereof followed by filtration or a centrifugation.
Examples Example 1
2-[[[4-(3-Methoxypropoxy)~3-methyl-2-pyridinyl]methyl]thio]-1H- benzimidazole (130 Kg) was dissolved in methylene chloride(780 L)1 stirred at 25 - 350C and cooled the reaction mass to 0 - 50C. Sodium hypochlorite solution (2%, 975 L) was added to the reaction mass for 1 hour 30 minutes at 0 - 50C and stirred. Ammonium sulphate (122 Kg), water (1000 L), methylene chloride (250 L) and sodium chloride (130 Kg) were added to the reaction mass, stirred for 30 minutes at 5 - 100C and allowed to settle for 15 minutes. The bottom organic layer was separated twice by treating with methylene chloride (2 x 250 L), stirred and allowed to settle for 15 minutes. Water (1300 L) and sodium hydroxide flakes (50 Kg) were added to the reactor, cooled to 20 - 250C and then added the methylene chloride layer to the reactor. Sodium chloride (50 Kg) was added to the reaction mixture, stirred for 20 minutes and allowed to settle for 20 minutes. The bottom organic layer was separated. The pH of the aqueous layer was adjusted to 9.2 - 9.4 with ammonium acetate solution (ammonium acetate: 52 Kg + water: 200 L) and acetic acid solution (acetic acid: 65 L + water: 200 L). The bottom organic layer was separated twice by treating with methylene chloride (2 x 650 L), stirred and allowed to settle for 15 minutes. The organic layer was given carbon treatment, filtered and washed the filtrate with methylene chloride (50 L). Dried the total organic layers with sodium sulfate (20 Kg) and 2-Amino ethanol (1.8 L) was added. The organic layer was concentrated until the mass temperature reached to 40 - 450C. Acetonitrile (50 L) was added to the reaction mass and acetonitrile was distilled off from the reaction mass until the mass temperature reached to 40 - 450C. Acetonitrile (600 L) was added to the reaction mass, stirred for 2 hours at room temperature and cooled to 0 - 50C. Centrifuged the material twice, washed with acetonitrile (2 x 50 L) and dried to give 90 Kg of crude rabeprazole. Taken Monomethylamine (135 L) in water (765 L), cooled to 10 - 200C, added crude rabeprazole and stirred for dissolution. The bottom organic layer was separated
twice by treating with methylene chloride (2 x 180 L), stirred and allowed to settle for 15 minutes. The pH of the aqueous layer was adjusted to 9.6 - 9.8 with ammonium acetate solution (ammonium acetate: 36 Kg + DM water: 140 L). The bottom organic layer was separated twice by treating with methylene chloride (2 x 450 L), stirred and allowed to settle for 15 minutes. The total organic layer was washed with sodiumchloride solution (sodium chloride: 36 Kg, DM water: 140 L), given carbon treatment, filtered, washed the filtrate with methylenechloride (50 L) and 2-amino ethanol (0.54 L) was added. The organic layer was concentrated until the mass temperature reached to 35 - 400C. Acetonitrile (90 L) was added to the reaction mass and acetonitrile was distilled off from the reaction mass until the mass temperature reached to 35 - 400C. Acetonitrile (270 L) was added to the reaction mass, cooled to 25 - 350C, stirred for 1 hour 30 minutes, cooled to 0 - 50C and stirred for 1 hour. Centrifuged the material, washed with acetonitrile (50 L) and dried the material to give 72 Kg of rabeprazole (HPLC purity: 99.8%). Sodium hydroxide (8.2 Kg) was dissolved in methanol (360 L).
Rabeprazole was added to the solution and stirred at 25 - 350C for 1 hour. Methanol was distilled off from the reaction mass, dichloromethane (150 L) was added to the residual mass and the contents were stirred to obtain solution. The solution was added to cyclohexane (1080 L). The contents were stirred at 25 - 350C for 30 minutes, centrifuged the material and washed at 60 - 650C to obtain 69 Kg of amorphous rabeprazole sodium.
Claims
We claim
1) A process for preparing amorphous rabeprazole sodium the said process comprises: a) Mixing a solution of rabeprazole sodium in a chlorinated solvent with cyclohexane, b) stirring the contents obtained in step (a) at 0-500C for at least 15 minutes, and c) isolating amorphous rabeprazole sodium from the contents obtained in step (b). 2) The process according to claim 1, wherein the solvent used in step (a) is methylene chloride.
3) The process according to claim 1 , wherein the step (b) is carried out at 20 - 350C for 15 to 75 minutes.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08808137A EP2294064A4 (en) | 2008-07-07 | 2008-07-07 | Process for purification of rabeprazole sodium |
| PCT/IN2008/000433 WO2010004571A2 (en) | 2008-07-07 | 2008-07-07 | Process for purification of rabeprazole sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2008/000433 WO2010004571A2 (en) | 2008-07-07 | 2008-07-07 | Process for purification of rabeprazole sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2010004571A2 true WO2010004571A2 (en) | 2010-01-14 |
| WO2010004571A3 WO2010004571A3 (en) | 2010-12-29 |
Family
ID=41507511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2008/000433 WO2010004571A2 (en) | 2008-07-07 | 2008-07-07 | Process for purification of rabeprazole sodium |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2294064A4 (en) |
| WO (1) | WO2010004571A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2391197A1 (en) * | 2011-04-27 | 2012-11-22 | Moehs Ibérica S.L. | Process for obtaining amorphous rabeprazole sodium |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060041224A (en) * | 2003-07-15 | 2006-05-11 | 알러간, 인코포레이티드 | How to prepare isomerically pure prodrugs of proton pump inhibitors |
| WO2006024890A1 (en) * | 2004-08-30 | 2006-03-09 | Apollo International Limited | Improved process for rabeprazole sodium in amorphous form |
| ATE495166T1 (en) * | 2005-03-30 | 2011-01-15 | Lupin Ltd | IMPROVED METHOD FOR PREPARING RABEPRAZOLE SODIUM |
| AR058440A1 (en) * | 2005-08-02 | 2008-02-06 | Medichem Sa | PROCESSES FOR THE PRODUCTION OF RABEPRAZOL SODICO AMORFO |
| US20100204478A1 (en) * | 2007-05-25 | 2010-08-12 | Hetero Drugs Limited | Improved process for amophous rabeprazole sodium |
-
2008
- 2008-07-07 WO PCT/IN2008/000433 patent/WO2010004571A2/en active Application Filing
- 2008-07-07 EP EP08808137A patent/EP2294064A4/en not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of EP2294064A4 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2391197A1 (en) * | 2011-04-27 | 2012-11-22 | Moehs Ibérica S.L. | Process for obtaining amorphous rabeprazole sodium |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2294064A4 (en) | 2011-10-05 |
| WO2010004571A3 (en) | 2010-12-29 |
| EP2294064A2 (en) | 2011-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8106210B2 (en) | Polymorphs of esomeprazole salts | |
| EP2030973A1 (en) | Process for preparing 2-sulfinyl-1H-benzimidazoles | |
| KR102027388B1 (en) | Process for preparing high purity ilaprazole crystalline form B | |
| RU2197486C2 (en) | Improved method of synthesis of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2- pyridyl)methyl]sulfinyl-1h-benzimidazole | |
| WO2009075516A2 (en) | Process for preparing pantoprazole sodium sesquihydrate | |
| JP5192707B2 (en) | Manufacturing method of mirtazapine | |
| WO2010004571A2 (en) | Process for purification of rabeprazole sodium | |
| US7081534B2 (en) | Process for the preparation of pantoprazole and salts thereof | |
| JP5355893B2 (en) | Method for producing pantoprazole sodium | |
| EP1476441B1 (en) | A method of eliminating sulfone analog in the synthesis of pyridine-benzimidazole sulfoxides | |
| EP2643308B1 (en) | Process for the preparation of taurolidine and its intermediates thereof | |
| WO2008017020A2 (en) | Process for preparing proton pump inhibitors | |
| CN106279108B (en) | A kind of method of industrialized production Rabeprazole and dextral-rabeprazole intermediate | |
| KR101694262B1 (en) | Process for preparing crystalline forms of silodosin | |
| WO2006080484A1 (en) | Cefcapene pivoxil methanesulfonate | |
| CN107365299B (en) | Preparation method of dabigatran etexilate and intermediate thereof | |
| US20110295016A1 (en) | A new process for preparing 4-[4-methyl-5-(cl-10alkylthio/c5-10aryl-cl-6alkylthio)-4h-1,2,4-triazol-3-yl]pyridines | |
| WO2024153856A1 (en) | Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide | |
| EP1818331A1 (en) | Process for the preparation of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole substantially free of sulfone impurity | |
| JPWO2006003946A1 (en) | Method for producing benzimidazole derivative salt precipitate | |
| JP2008137895A (en) | Method for preparing s-pantoprazole | |
| JP2019059688A (en) | Process for producing crystalline L-carnosine zinc complex | |
| HK1235396A1 (en) | Process for large scale production of 1-isopropyl-3-{5- [1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}- 1h-indazole oxalate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08808137 Country of ref document: EP Kind code of ref document: A2 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008808137 Country of ref document: EP |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |